The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / HSCT for Severe Autoimmune Diseases

HSCT for Severe Autoimmune Diseases

August 14, 2017 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Despite the innovations of new biologics and disease-modifying anti-rheumatic drugs, a large unmet need remains for patients with rheumatic autoimmune disease. Treatment remains limited for many conditions, including for conditions with a dim prognosis, such as systemic sclerosis.1 One promising treatment avenue is hematopoietic stem-cell transplantation (HSCT). Here, we provide background on HSCT for severe rheumatic autoimmune disease, examine the perspectives of three patients who sought out clinical trials and provide a research update on systemic sclerosis.

You Might Also Like
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • T Cells & Autoimmune Diseases
Explore This Issue
August 2017
Also By This Author
  • Study Probes New Gene Therapy for Severe, Localized Scleroderma (Morphea)

HSCT History & Current Status

In 1996, a patient with connective tissue disease and severe pulmonary hypertension underwent autologous HSCT—the first patient with rheumatic autoimmune disease reported to receive the treatment.2 Since that time, clinical research teams have performed HSCT for a number of different rheumatic autoimmune conditions, including systemic sclerosis, lupus, rheumatoid arthritis, juvenile idiopathic arthritis and, less commonly, for other conditions, such as Sjögren’s syndrome, mixed connective tissue disease, Behçet’s disease, psoriatic arthritis, ankylosing spondylitis and vasculitides.3,4

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Worldwide, teams have performed over 3,000 HSCT procedures for rheumatic and nonrheumatic autoimmune disease. These have been mostly autologous HSCT, as documented through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation.3

Researchers adopted the technique of HSCT from the fields of hematology and oncology.4 HSCT aims to reset an auto­reactive immune system. Current immunosuppressive and biological treatments for autoimmune rheumatological disease can successfully suppress immune response, but they are unable to target autoreactive immunologic memory. Moreover, they must be taken continuously in order to maintain immunosuppression. In contrast, HSCT therapies can potentially provide sustained, total remission of autoimmune syndromes without the need for ongoing therapy.

Dr. Georges Georges

Dr. Georges Georges

HSCT profoundly depletes the autoreactive immunologic memory (T cells and B cells) via high-dose chemotherapy. Conditioning regimens vary. In general though, stem cells are mobilized into the bloodstream by such treatments as granulocyte colony-stimulating factor and later collected. Several weeks later, patients undergo some version of immunoablative therapy, receiving such agents as anti-thymocyte globulin and cyclophosphamide. During this time, the autoreactive immunological memory is profoundly depleted. This is followed by autologous stem cell transplant, which reconstitutes a new immune system and reestablishes immune tolerance.3

After transplant, T cells appear to be largely derived from the stem-cell graft, and T regulatory cells display a renewed repertoire of T cell receptors.3,5 Autoantibodies are also substantively reduced after HSCT treatment.5

Kathy Peel had HSCT for her lupus in July 2016.

Kathy Peel had HSCT for her lupus in July 2016.

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions Tagged With: Autoimmune, Biologics, Clinical, disease-modifying anti-rheumatic drugs, hematopoietic stem-cell transplantation, Juvenile idiopathic arthritis, Lupus, outcome, patient care, Research, Rheumatic Disease, Rheumatoid arthritis, rheumatology, Systemic sclerosis, TreatmentIssue: August 2017

You Might Also Like:
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • T Cells & Autoimmune Diseases
  • Cellular Therapy of Autoimmune Disease

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.